secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0000950170-23-023505
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics reports positive Phase 2 data for aficamten in nHCM; Phase 3 to start 2H 2023
--------------------------------------------------------------------------------

- At 10 weeks, aficamten improved KCCQ-CSS by 10.6 points (p<0.0001); 58% of patients had clinical symptom reduction.
- 56% of patients improved ≥1 NYHA class; 28% became asymptomatic (Class I) by Week 10.
- Mean relative reductions: NT-proBNP 55% (p<0.0001) and high-sensitivity troponin I 21% (p<0.005).
- In 14 patients with baseline angina, SAQ-AF score reduced 14.3 points (p=0.005), converting daily/weekly angina to weekly/monthly.
- Aficamten well-tolerated; no discontinuations due to AEs, no LVEF<40%, and phase 3 trial planned for 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023023505/0000950170-23-023505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023023505/cytk-20230520.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-023505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer